会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • MULTI INPUT MULTI OUTPUT (MIMO) ORTHOGONAL FREQUENCY DIVISION MULTIPLE ACCESS (OFDMA) COMMUNICATION SYSTEM
    • 多输入多输出(MIMO)正交频分多址(OFDMA)通信系统
    • WO2007142858A2
    • 2007-12-13
    • PCT/US2007012401
    • 2007-05-24
    • TELECIS WIRELESS INCPARK JONG HYEONPARK JU WONKIM JE WOO
    • PARK JONG HYEONPARK JU WONKIM JE WOO
    • H04L1/02H04L27/00
    • H04L1/0015H04B7/0417H04B7/0608H04B7/0689H04B7/0814H04B7/0871H04L1/0001H04L1/06H04L27/2608
    • An embodiment of the present invention is a technique to process signals in a communication system. In one embodiment, a plurality of signal processing units processes signals received from a plurality of antennae. The signal processor units are controlled by operational mode control signals. A channel estimator estimates channel responses using the processed signals according to an operational mode. An equalizer and combiner generates an equalized and combined signal using the received signals and the estimated channel responses. A Carrier to Interference Noise Ratio (CINR) estimator estimates CINR from the equalized and combined signal, The estimated CENR is used to generate the operational mode control signals. In another embodiment, a sub-carrier allocation controller generates sub-carrier allocation signals using an allocation base. A channel status information (CSI) and multiple input multiple output (MMO) controller generates sub- carrier CSI signals and operational mode control signals using the sub-carrier allocation signals, estimated channel responses provided by.a channel estimator, and an estimated CINR provided by an CINR estimator. The operational mode control signals select one of a plurality of antenna paths associated with a plurality of antennae. A transmitter diversity processor generates transmitter diversity signals as a function of at least a mapped signal Mk, the sub-carrier CSI signals, and the operational mode control signals.
    • 本发明的实施例是一种在通信系统中处理信号的技术。 在一个实施例中,多个信号处理单元处理从多个天线接收的信号。 信号处理器单元由操作模式控制信号控制。 信道估计器根据操作模式使用经处理的信号来估计信道响应。 均衡器和组合器使用接收的信号和估计的信道响应产生均衡和组合的信号。 载波干扰噪声比(CINR)估计器从均衡和组合信号估计CINR,估计的CENR用于生成操作模式控制信号。 在另一实施例中,子载波分配控制器使用分配基地产生副载波分配信号。 信道状态信息(CSI)和多输入多输出(MMO)控制器使用子载波分配信号,由信道估计器提供的估计信道响应和估计的CINR来产生子载波CSI信号和操作模式控制信号 由CINR估计器。 操作模式控制信号选择与多个天线相关联的多个天线路径之一。 发射机分集处理器生成作为至少映射信号Mk,子载波CSI信号和操作模式控制信号的函数的发射机分集信号。
    • 6. 发明申请
    • COMBINED FORMULATION WITH IMPROVED STABILITY
    • 具有改进的稳定性的组合配方
    • WO2012124973A3
    • 2012-11-08
    • PCT/KR2012001828
    • 2012-03-14
    • BORYUNG PHARMKIM JE HAKNAM KYUNG WANPARK JU WON
    • KIM JE HAKNAM KYUNG WANPARK JU WON
    • A61K9/16A61K9/28A61K31/60A61P7/02
    • A61K9/51A61K9/2866A61K9/4808A61K9/5042A61K9/5084A61K31/22A61K31/40A61K31/47A61K31/505A61K31/60A61K31/616A61K45/06A61K2300/00
    • Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.
    • 公开了用于治疗心血管疾病的口服给药的组合制剂,包括(a)直径为7.5mm以下的胆固醇降低剂微片,其含有胆固醇降低剂,其稳定剂和药学上可接受的赋形剂,并且具有 涂布层,以及(b)直径为7.5mm以下的抗血栓形成剂微片或微丸,其含有抗血栓剂和药学上可接受的赋形剂,并且在其表面包括肠溶衣膜。 该制剂可以根据组合处方改善治疗依从性,并且被控制以使胆固醇降低剂在胃肠道中释放,并且抗血栓形成剂在肠中释放,从而抑制药物之间的反应和副作用, 诱导这些药物在体内的协同作用,并达到改善的稳定性。